3 results
Primary:To evaluate if progression-free survival from randomization to progression or death during second-line therapy (total PFS) of sorafenib followed by pazopanib is non-inferior compared to pazopanib followed by sorafenib.Secondary:1. Time from…
Primary Objective: To determine whether topical application of Calcitriol (Silkis) 3 µg/g, Diclofenac 10% or a combination of both can lead to a 40% histological reduction (*)/increase (*) of expression of the following antibodies: Ki67 (*), BCL2…
Primary ObjectivesTo evaluate the safety and efficacy of 2 fixed doses of EVP-6124 hydrochloride (HCl) ( 2 or 3 mg daily) compared to placebo for 26 weeks in subjects with mild to moderate dementia due to Alzheimer*s disease (AD) currently receiving…